Antigen News and Research

RSS

Wits University begins South African trial of Novavax COVID-19 vaccine

NVX-CoV2373 is produced by the biotech company, Novavax (Maryland, U.S.A). Novavax is a late-stage biotechnology company that develops next-generation vaccines for serious infectious diseases.

17 Aug 2020

New type of immunotherapy extends survival of mice with triple negative breast tumors

Immunotherapies for cancer -; treatments that prime the immune system to attack tumors -; are valuable weapons in the anti-cancer arsenal. But some cancers are more difficult to target with this strategy than others.

17 Aug 2020

Scientists claim signs of lasting SARS-CoV-2 immunity

Questions have been raised by many health experts on whether being infected with SARS-CoV-2 brings lasting immunity. Now, scientists have uncovered signs of strong and lasting immunity in people who even had a mild illness of COVID-19.

17 Aug 2020

Coronacept - A trap-and-destroy molecule against SARS-CoV-2

A new study published on the preprint server bioRxiv* in August 2020 reports a novel engineered molecule based on human and other mammalian orthologues of ACE2 fused with the Fc part of the antibody. This molecule interacts more tightly with the viral receptor-binding domain (RBD) to constitute a powerful immunoadhesin that targets the virus for destruction.

17 Aug 2020

Targeting SARS-CoV-2 with off-the-shelf CAR-NK cells

The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread and cause disease and death in many countries even today. At present, there is no effective treatment. A recent study published on the preprint server bioRxiv in August 2020 reports the potential of a new class of drugs called CAR NK cells, which could be used off-the-shelf to treat this disease.

17 Aug 2020

PARP inhibitor can successfully treat a subset of advanced prostate cancer patients

Results from an international clinical trial found that men with advanced prostate cancer who have mutated BRCA1/BRCA2 genes can be treated successfully with a targeted therapy known as rucaparib, resulting in recent FDA approval.

15 Aug 2020

Influenza-virus-based vaccine platform another viable option against SARS-CoV-2

In a novel proof of concept study, published on the bioRxiv preprint server, U.S. researchers used attenuated influenza viral particles that express severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain to induce neutralizing antibodies in mice – unveiling another viable vaccine candidate for preventing coronavirus disease (COVID-19).

14 Aug 2020

De novo designed SARS-CoV-2 nanoparticle vaccine

In light of the continuing threat to public health, social functioning, and economic activity posed by the COVID-19 pandemic, scientists are working urgently to bring out a vaccine that is both safe and effective, and capable of mass production. A new paper published on the preprint server bioRxiv* in August 2020 shows that such a vaccine may be produced by using arrays of one severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein on a nanoparticle platform.

14 Aug 2020

Developing a blood test for prostate cancer

Professor Pockley among researchers from the John van Geest Cancer Research Centre have recently developed a blood test for the detection of prostate cancer.

13 Aug 2020

Promega introduces new serological antibody test for COVID-19

Promega Corporation today announced the launch of its new serological antibody test for COVID-19 to detect the presence of antibodies against the SARS-CoV-2 virus.

From Promega Corporation 13 Aug 2020

C-type lectin receptors play a role in SARS-CoV-2 infection

A new study published on the preprint server bioRxiv in August 2020 confirms and extends earlier findings showing that a type of sugar-based receptor on innate immune cells promotes the entry of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into other cells that carry the viral receptor, angiotensin-converting enzyme 2 (ACE2).

12 Aug 2020

Research looks at convalescent plasma use in COVID-19 mouse model

A new study by researchers at the University of Iowa and published on the preprint server bioRxiv in August 2020 reports the utility of a mouse model that recapitulates several aspects of human COVID-19 and can reflect the antiviral efficacy of new drugs as well.

12 Aug 2020

COVID-19 patient with repeatedly undetectable SARS-CoV-2 antibodies

A recent case study published in the Journal of Applied Laboratory Medicine in August 2020 illustrates this with its finding of persistent seronegativity in a patient confirmed to be SARS-CoV-2 positive.

10 Aug 2020

Encouraging results from Phase I NovaVax SARS-CoV-2 nanoparticle vaccine trial

NVX-CoV2373, a recombinant nanoparticle vaccine developed by Novavax and manufactured at Emergent Biosolutions, was found to be well tolerated and immunogenic – inducing T-cell response and neutralization antibodies four-fold higher than the mean observed in hospitalized coronavirus disease (COVID-19) patients, shows a recent study available on the medRxiv* preprint server.

9 Aug 2020

New platform shows potential to generate most effective vaccines with fewest side effects

The ongoing COVID-19 pandemic is shining a bright spotlight on vaccine development. As numerous vaccines race through clinical trials, physicians and researchers continue to work on developing new vaccine technologies to generate the most effective vaccines with the fewest side effects.

7 Aug 2020

Scientists find new way of identifying and targeting hidden HIV viral reservoirs during ART therapy

Scientists at The Wistar Institute may have discovered a new way of identifying and targeting hidden HIV viral reservoirs during treatment with antiretroviral therapy (ART).

7 Aug 2020

Study identifies five immune response markers that may predict COVID-19 patient outcomes

Galit Alter, PhD, Group Leader at the Ragon Institute of MGH, MIT and Harvard and Professor of Medicine at Harvard Medical School, and Helen Chu, MD, Associate Professor of Medicine, Division of Allergy and Infectious Diseases, University of Washington School of Medicine, and UW Medicine physician, have recently published a paper which identifies five immune response markers which, collectively, were able to correctly classify both convalescent COVID-19 patients and those who did not survive the disease.

7 Aug 2020

Gene could predict treatment response in certain breast cancer patients

Scientists have identified a gene which if present in certain breast cancer patients indicates how they will respond to specific therapies.

6 Aug 2020

Fujirebio announces launch of clinical testing for new SARS-CoV-2 Antigen assay

Fujirebio Diagnostics, Inc., a consolidated subsidiary of H.U. Group Holdings, Inc, announced today the initiation of clinical testing needed for the submission of its new SARS-CoV-2 Antigen assay for EUA (Emergency Use Authorization) from the U.S. Food and Drug Administration.

6 Aug 2020

Avacta appoints COVID-19 rapid antigen test manufacturing partner

Avacta Group plc is pleased to announce that it has appointed BBI Solutions to manufacture the saliva-based rapid SARS-CoV-2 antigen test.

From Avacta Life Sciences Ltd. 6 Aug 2020

Antigen News and Research

Wits University begins South African trial of Novavax COVID-19 vaccine

New type of immunotherapy extends survival of mice with triple negative breast tumors

Scientists claim signs of lasting SARS-CoV-2 immunity

Coronacept - A trap-and-destroy molecule against SARS-CoV-2

Targeting SARS-CoV-2 with off-the-shelf CAR-NK cells

PARP inhibitor can successfully treat a subset of advanced prostate cancer patients

Influenza-virus-based vaccine platform another viable option against SARS-CoV-2

De novo designed SARS-CoV-2 nanoparticle vaccine

Developing a blood test for prostate cancer

Promega introduces new serological antibody test for COVID-19

C-type lectin receptors play a role in SARS-CoV-2 infection

Research looks at convalescent plasma use in COVID-19 mouse model

COVID-19 patient with repeatedly undetectable SARS-CoV-2 antibodies

Encouraging results from Phase I NovaVax SARS-CoV-2 nanoparticle vaccine trial

New platform shows potential to generate most effective vaccines with fewest side effects

Scientists find new way of identifying and targeting hidden HIV viral reservoirs during ART therapy

Study identifies five immune response markers that may predict COVID-19 patient outcomes

Gene could predict treatment response in certain breast cancer patients

Fujirebio announces launch of clinical testing for new SARS-CoV-2 Antigen assay

Avacta appoints COVID-19 rapid antigen test manufacturing partner

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest Life Science News